74%
inwestorów detalicznych traci pieniądze podczas handlu CFD z tym dostawcą.
Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej.
74%
rachunków inwestorów detalicznych notuje stratę pieniędzy podczas handlu kontraktami CFD z tym dostawcą.
Upewnij się, czy rozumiesz, jak działają kontrakty CFD, i czy możesz pozwolić sobie na wysokie ryzyko utraty pieniędzy.
74%
inwestorów detalicznych traci pieniądze podczas handlu CFD z tym dostawcą.
Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej.
74%
rachunków inwestorów detalicznych notuje stratę pieniędzy podczas handlu kontraktami CFD z tym dostawcą.
Upewnij się, czy rozumiesz, jak działają kontrakty CFD, i czy możesz pozwolić sobie na wysokie ryzyko utraty pieniędzy.
Bio-Techne Corp
Closed
SectorHealthcare
65.87 -0.23
Overview
Share price change
24h
Min
65.74
Max
66.29
Income | -40M -18M |
|---|---|
Sales | 783K 317M |
P/E Sector Avg | 135.957 37.461 |
EPS | 0.53 |
Dividend yield | 0.52 |
Profit margin | -5.577 |
Employees | 3,100 |
EBITDA | -61M 6.4M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +1.97% upside |
Dividend yield Sector Avg | 0.52% 2.33% |
|---|---|
Next Earnings | 5 lis 2025 |
Next Dividend date | 21 lis 2025 |
Next Ex Dividend date | 10 lis 2025 |
Market Cap | 847M 9.7B |
|---|---|
Previous open | 66.1 |
Previous close | 65.87 |
News Sentiment
By Acuity
50%
50%
147 / 371 Ranking in Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Bio-Techne Corp Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Bio-Techne Corp Forecast
Price Target
By TipRanks
1.97% upside
12 Months Forecast
Average 67.2 USD 1.97%
High 75 USD
Low 53 USD
Based on 13 Wall Street analysts offering 12 month price targets forBio-Techne Corp - Dist in the last 3 months.
Sentiment
By Acuity
147 / 371 Ranking in Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Live chat